The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.
 
Kevin Joseph Harrington
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Codiak Biosciences (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst)
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Replimune (Inst)
 
Joseph J. Sacco
Honoraria - Immunocore; Novartis; Pierre Fabre
Consulting or Advisory Role - BMS; Delcath Systems; Immunocore; Immunocore (Inst); MSD
Research Funding - AstraZeneca (Inst); BMS (Inst); Immunocore (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Anna Claire Olsson-Brown
Honoraria - Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Lilly (Inst); Novartis; Roche (Inst); UCB (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; SERVIER
 
Tze Y Chan
No Relationships to Disclose
 
Pablo Nenclares
No Relationships to Disclose
 
Isla Leslie
No Relationships to Disclose
 
Imran Saleem
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Praveen Bommareddy
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Christoph Matthias Ahlers
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Robert S. Coffin
Employment - Replimune
Leadership - Replimune
Stock and Other Ownership Interests - Replimune
 
Mark R. Middleton
Consulting or Advisory Role - Alkermes; Bayer; BiolineRx; Boehringer Ingelheim; Bristol-Myers Squibb; Immunocore; Kineta; Merck; Silicon Therapeutics; Vaccitech
Research Funding - Amgen (Inst); AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Immunocore (Inst); Medivir (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Salvarx (Inst); Vaccitech (Inst)
(OPTIONAL) Uncompensated Relationships - GenesisCare